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Lessons LearnedHuman brain tissue, even at the stroke cavity area, may maintain its regenerative capacity for 2 or more years after stroke.Implantation of neural stem cells may trigger the release of such regenerative capacity. Significance StatementSeveral different cell types have been proposed and tested in preclinical models and clinical trials to treat neurological conditions. However, few have shown significant properties to differentiate into genuine neuronal phenotypes or capability to integrate into the central nervous system (CNS) tissue, which are expected to be prerequisite properties for long‐lasting benefits. NSI‐566 is an adherent neural stem cell line that differentiates, matures, and integrates into the CNS tissue. This study presents evidence supporting stable allogeneic neural tissue formation by the stem cells in the brains of chronic stroke patients, suggesting statistically significant clinical benefits from baseline as measured by three different validated stroke scales.

Introduction {#sct312527-sec-0003}
============

Neural stem cells are the precursor cells present in the neuroepithelium along the neuraxis during mammalian fetal development [1](#sct312527-bib-0001){ref-type="ref"}. Neuralstem, Inc. (NSI)‐566, the investigational product used in this study, is a stable, primary cell line consisting of neural stem cells derived from a single human fetal spinal cord tissue and expanded only by epigenetic means with no genetic modification [2](#sct312527-bib-0002){ref-type="ref"}. This cell line is being tested in clinical trials in the U.S. for treatment of amyotrophic lateral sclerosis (ALS; NCT01348451, NCT01730716) and spinal cord injury (SCI; NCT01772810; [ClinicalTrials.gov](https://ClinicalTrials.gov) identifier: NCT03296618). A variety of preclinical and clinical studies have demonstrated the therapeutic potential of NSI‐566 for reversing paralysis due to various neurological etiologies.

Studies in ALS rodent models have shown that NSI‐566 effectively engrafts in lesioned tissue, survives for many months, integrates into the host motor neuron circuitry, forms contacts on host motor neurons, and expresses multiple growth factors, resulting in decreased loss of α‐motor neurons and increased lifespan [3](#sct312527-bib-0003){ref-type="ref"}, [4](#sct312527-bib-0004){ref-type="ref"}, [5](#sct312527-bib-0005){ref-type="ref"}, [6](#sct312527-bib-0006){ref-type="ref"}, [7](#sct312527-bib-0007){ref-type="ref"}. In studies with rat contusion model of SCI, grafted NSI‐566 survived in the necrotic tissue, proliferated to fill in the lesion cavity, and then differentiated en masse into neurons, which were seen to project into the host tissue while the host neuronal fibers traversed across the human graft. Markers of mature human neurons, neurites, and synapses were colocalized with the host descending motor tracts [8](#sct312527-bib-0008){ref-type="ref"}, [9](#sct312527-bib-0009){ref-type="ref"}. In another rat model of permanent paraplegia where the spinal cord was surgically transected at segment T3, intraspinal grafting of NSI‐566 into the gap produced by the transection resulted in partial motor recovery. Histology showed NSI‐566‐derived neurons extending axons over 17 spinal segments. Formation of new relay circuits by the transplanted cells was thought to result in the improved function [10](#sct312527-bib-0010){ref-type="ref"}. In a recent study of monkeys with hemitransection induced SCI, NSI‐566 grafted into the lesion site demonstrated robust neuronal differentiation and long‐distance axonal projections below the level of injury, which were shown to synapse with the monkey motor neurons in the segments caudal to the injury. The monkeys showed significant motor improvement, including hand manipulation [11](#sct312527-bib-0011){ref-type="ref"}.

Finally, two additional studies support a therapeutic role for NSI‐566 in rodent models of ischemic injury. In a rat model of ischemic SCI in which ischemia‐induced spasticity and rigidity accompanies permanent incomplete paraplegia, intraspinal grafting of NSI‐566 into the lumbar gray matter resulted in progressive recovery of motor function and correlative improvement in motor evoked potentials over 2--3 months after grafting [12](#sct312527-bib-0012){ref-type="ref"}. In rats with ischemic stroke induced by transient occlusion of the middle cerebral artery, NSI‐566 transplantation into subcortical regions 7 days poststroke resulted in motor improvement in a dose‐dependent manner [13](#sct312527-bib-0013){ref-type="ref"}. Thus, NSI‐566 has consistently demonstrated robust neuronal differentiation, maturation, integration, and survival for many months even in xenotransplantation when sufficient immunosuppression tolerated xenograft survival.

Three clinical studies have been conducted with NSI‐566 allotransplantation: two ALS studies (*n* = 30) and one chronic SCI study (*n* = 4), amounting to a total of 34 participants, and 2--6 years of human safety/efficacy monitoring so far. These studies\' results provide evidence that NSI‐566 can survive in the host parenchyma for at least 2.5 years, even with transient immunosuppression, is safe, and can provide clinical benefits in patients with neurological damage [14](#sct312527-bib-0014){ref-type="ref"}, [15](#sct312527-bib-0015){ref-type="ref"}, [16](#sct312527-bib-0016){ref-type="ref"}, [17](#sct312527-bib-0017){ref-type="ref"}, [18](#sct312527-bib-0018){ref-type="ref"}, [19](#sct312527-bib-0019){ref-type="ref"}. Phases I and II ALS subjects who received NSI‐566 showed significant functional stabilization as well as significantly better composite functional/survival score at 24 months compared with historical controls [18](#sct312527-bib-0018){ref-type="ref"}. Furthermore, in a phase I study, three out of four complete paraplegic SCI patients with thoracic cord injuries who received NSI‐566 transplantation exhibited new acquisition of voluntary muscle units and two of them showed neurological improvement below the level of injury [19](#sct312527-bib-0019){ref-type="ref"}.

Paralysis due to ischemic stroke is a major cause of prolonged neurological disability worldwide, particularly in China and other Asian countries [20](#sct312527-bib-0020){ref-type="ref"}. There are currently no effective therapies to reverse stroke‐associated paralysis. We have investigated the feasibility and safety of transplanting NSI‐566 to reverse the paralysis in nine stably hemiparetic stroke patients.

Materials and Methods {#sct312527-sec-0004}
=====================

Preparation of the Stem Cells {#sct312527-sec-0005}
-----------------------------

Details of NSI‐566 derivation and manufacture have been previously described [16](#sct312527-bib-0016){ref-type="ref"}. Briefly, NSI‐566 is a stable line of expanded human neural stem cells derived from a single human fetal spinal cord tissue of approximately eight gestational weeks. No genetic modification was introduced to the cells. Concentrated, ready‐to‐inject cell doses from a clinical lot of passage 12 cells were prepared as live cell suspensions the day before surgery and couriered at 2°C--8°C to the transplantation surgery site in the morning of surgery. In this formulation, the product is usable for 48 hours from the time of preparation. The cell suspension was tested for acceptable cell viability (≥70%) by trypan blue exclusion method and administered into patients without further manipulation.

Participants {#sct312527-sec-0006}
------------

Between 2013 and 2016, potentially eligible subjects were selected from the hospital database, prescreened by telephone interview, underwent review of their medical and MRI records, and then received onsite screening. All nine subjects who met the initial screen eligibility received the stem cells treatment ("intent‐to‐treat" population). The participants were men and women 30--65 years old with hemiparesis from ischemic stroke and who remained stable based on National Institutes of Health Stroke Scale (NIHSS) assessments for at least 3 weeks prior to the surgery. All subjects had to have chronic motor deficit for at least 3 months but not more than 24 months from the time of stroke, with modified Rankin Scores (MRSs) of 2, 3, or 4 and Fugl‐Meyer Motor Scores of 55 or less, at the initial screening. All study participants were Chinese and signed informed consent form. As this was a feasibility study, no attempt was made to balance the gender. All transplantation surgeries and follow‐up assessments were performed at BaYi Brain Hospital, Beijing, China, with approval by the hospital ethics committee.

Study Design {#sct312527-sec-0007}
------------

Three doses were tested: a total 1.2 × 10^7^ cells (cohort A) distributed via 15 cell deposits, each consisting of 20 μl of 40,000 cells per microliter in three cannula tracks; a total 2.4 × 10^7^ cells (cohort B) distributed via 15 cell deposits, each consisting of 20 μl of 80,000 cells per microliter in three cannula tracks; and a total 7.2 × 10^7^ cells (cohort C) distributed via 45 cell deposits, each consisting of 20 μl of 80,000 cells per microliter in three cannula tracks. A straight cannula of Pittsburgh Design [21](#sct312527-bib-0021){ref-type="ref"} was used for cohorts A and B (FHC, New Hampshire). A novel cannula design, intracerebral microinjection instrument with a side exit port was used for cohort C [22](#sct312527-bib-0022){ref-type="ref"}, [23](#sct312527-bib-0023){ref-type="ref"} (FHC). Each successive dose had to be tolerated by all three patients before advancing to the next dose cohort. A safety monitoring board reviewed the safety of all patients prior to approving the next dose cohort. Follow‐ups for the participants were planned for a period of 24 months post‐transplantation and are reported here. Additional details of the methods used are provided in [Supporting Information](#sct312527-supitem-0001){ref-type="supplementary-material"}.

Results {#sct312527-sec-0008}
=======

Treatment Assignment {#sct312527-sec-0009}
--------------------

Nine participants in total were planned and enrolled successively in order of three dose cohorts of 12, 24, and 72 million cells (*n* = 3 per cohort, Table [1](#sct312527-tbl-0001){ref-type="table"}). All participants have completed 12--24 months of scheduled follow‐up visits.

###### 

Treatment assignment

  Cohort ID     Treatment          Cell number/deposit                   No. of deposits/cannula track   No. of cannula tracks
  ------------- ------------------ ------------------------------------- ------------------------------- -----------------------
  A (*n* = 3)   12 million cells   40,000 cells per microliter × 20 μl   5                               3
  B (*n* = 3)   24 million cells   80,000 cells per microliter × 20 μl   5                               3
  C (*n* = 3)   72 million cells   80,000 cells per microliter × 20 μl   15                              3

Demographics and Safety {#sct312527-sec-0010}
-----------------------

The functional impairment for eight of nine subjects enrolled was of moderate disability, requiring some help but with the ability to walk without assistance (MRS grade 3). The remaining subject (\#107) was of moderately severe disability, unable to walk and unable to self‐care without assistance (MRS grade 4). Motor deficit as determined by Fugl‐Meyer Motor Score (FMMS, total score of 100), which had to be 55 or less for inclusion in the study, ranged from 19 to 48 among subjects. Three cases were of stroke in the left hemisphere and six cases were in the right hemisphere. The longest infarct dimension ranged from 17.2 to 86.6 mm. Subjects received the stem cell treatment 150--743 days poststroke event (Table [2](#sct312527-tbl-0002){ref-type="table"}).

###### 

Participant characteristics at baseline

  Subject no.                                    Gender (F/M)  Age   Weight (kg)   Stroke location, volume (ml)[a](#sct312527-note-0002){ref-type="fn"}   Days poststroke[b](#sct312527-note-0003){ref-type="fn"}   NIHSS[c](#sct312527-note-0004){ref-type="fn"}   MRS[d](#sct312527-note-0005){ref-type="fn"}   FMMS[c](#sct312527-note-0004){ref-type="fn"}    Treatment cohort
  --------------------------------------------- -------------- ----- ------------- ---------------------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------- --------------------------------------------- ---------------------------------------------- ------------------
  101                                                 M        50    78            Infarct, L, SC, 10.29                                                  607                                                       9                                               3                                             32                                                     A
  102                                                 M        47    75            Infarct, R, SC, 6.44                                                   424                                                       2                                               3                                             29                                                     A
  103[e](#sct312527-note-0006){ref-type="fn"}         M        30    90            Infarct, R, SC, 4.17                                                   150                                                       5                                               3                                             39                                                     A
  104[e](#sct312527-note-0006){ref-type="fn"}         M        44    70            Infarct, R, SC, 7.01                                                   519                                                       10                                              3                                             19                                                     B
  105[e](#sct312527-note-0006){ref-type="fn"}         M        41    75            Infarct, R, SC, 71.15                                                  357                                                       7                                               3                                             41                                                     B
  106                                                 M        45    75            Infarct, L, SC, 4.09                                                   743                                                       6                                               3                                             41                                                     B
  107                                                 M        56    59            Infarct, L, SC, 13.31                                                  417                                                       7                                               4                                             27                                                     C
  108                                                 M        38    71            Infarct, R, SC, 0.86                                                   719                                                       5                                               3                                             17                                                     C
  109                                                 F        54    52            Infarct, R, SC, 0.81                                                   517                                                       6                                               3                                             48                                                     C

Volume was calculated in cubic centimeters from baseline T1 voxel counts in the lesion.

At the time of stem cell administration.

Determined at screen 2.

Determined at screen 1 (not performed at screen 2).

Withdrew consent after month 12 visit.

Abbreviations: F, female; FMMS, Fugl‐Meyer Motor Score; L, left; M, male; MRS, modified Rankin Score; NIHSS, National Institutes of Health Stroke Scale; R, right; SC, subcortical.

The mean age of participants was 44 (minimum 30, maximum 54) with the mean NIHSS score of 6.3, mean FMMS (total 100) of 32.6, and mean MRS of 3.1. The baseline stroke characteristics were similar across the dose cohorts (Table [3](#sct312527-tbl-0003){ref-type="table"}).

###### 

Mean demographics and safety results

                          Cohort A (*n* = 3)                               Cohort B (*n* = 3)   Cohort C (*n* = 3)   Pooled cohort (*n* = 9)
  ----------------------- ------------------------------------------------ -------------------- -------------------- ------------------------------------------------
  Age: mean (range)       42 (30--49)                                      43 (41--45)          48 (37--54)          44 (30--54)
  Sex: male/female        3/0                                              3/0                  2/1                  8/1
  NIHSS mean (SEM)        5.3 (2.0)                                        7.7 (1.2)            6.0 (0.6)            6.3 (0.8)
  MRS mean (SEM)          3.0 (0.0)                                        3.0 (0.0)            3.3 (0.3)            3.1 (0.1)
  FMMS mean (SEM)         33.3 (3.0)                                       33.7 (7.3)           30.7 (9.1)           32.6 (3.5)
  AE/SAE/death reported   18/2[a](#sct312527-note-0008){ref-type="fn"}/0   2/0/0                15/0/0               35[b](#sct312527-note-0009){ref-type="fn"}/2/0

Cholecystitis (grade 3), unrelated to surgery.

Thirty‐five total AEs involved seven subjects, of which 30 were resolved without sequelae, two incidences from cholecystitis were reported as having changed in status, and three continuing (\#107 constipation; \#108 pruritus and weight gain).

Abbreviations: AE, adverse event; FMMS, Fugl‐Meyer Motor Score; MRS, modified Rankin Score; NIHSS, National Institutes of Health Stroke Scale; SAE, serious adverse event.

Safety Assessments {#sct312527-sec-0011}
------------------

Follow‐up visits for safety and exploratory outcomes were scheduled at 1, 3, 6, 9, 12, and 24 months postoperative day of stem cell treatment. Safety assessments included computed tomography (CT) scan on the day of surgery or the following day to monitor potential hemorrhage, and at scheduled visits for physical exam, laboratory monitoring, and clinical stroke evaluations as well as periodic imaging studies by MRI.

There were 35 reported adverse events (AEs) during the study (Table [3](#sct312527-tbl-0003){ref-type="table"}). The injection times for 15 versus 45 cell deposits averaged 1:42 versus 4:32 (hour:minute). However, no increased AEs were apparent among the dose groups (18, 2, 15 for groups A, B, and C, respectively). Two subjects experienced serious AEs. One subject reported cholecystitis twice (shown in Supporting Information, Table [S3](#sct312527-supitem-0001){ref-type="supplementary-material"}). Related to CNS, there was one case of microcerebral hemorrhage (\#102) detected by prescheduled CT scan, which required no intervention and resolved without sequelae. Two incidences of mild seizures (\#101 and \#102) were reported, which were treated with antiseizure medications and resolved without sequelae.

All participants received 28 days of oral tacrolimus to maintain 4--8 ng/ml trough blood level for immunosuppression, as well as 14 days of prednisone postsurgery as an anti‐inflammatory measure. Both drugs were well tolerated by all participants. All patients were discharged from the hospital after 14 days, as scheduled. Subsequent monitoring for appearance of antibodies against human leukocyte antigen (HLA) class I and II antigens was negative for all nine subjects.

Clinical Outcome {#sct312527-sec-0012}
----------------

Twelve‐month (*n* = 9) or 24‐month (*n* = 6) follow‐up data of the combined participants across the three dose groups were analyzed for clinical changes. Wilcoxon signed rank test was used. At the 12th month visit, the mean FMMS (total score of 100) showed 16.0 points of improvement from baseline (*p* = .0078, Fig. [1](#sct312527-fig-0001){ref-type="fig"}B). FMMS improvement was statistically significant at months 1, 3, 6, and 9 as well. The mean MRS at 12‐month visit showed 0.8 points of improvement from baseline (*p* = .031, Fig. [1](#sct312527-fig-0001){ref-type="fig"}C). The MRS improvement was also statistically significant at months 3 and 9 as well. The mean NIHSS at 12‐month visit showed a statistically significant improvement of 3.1 points from baseline (*p* = .020, Fig. [1](#sct312527-fig-0001){ref-type="fig"}D). The improvements were maintained at 24‐month visit. The stem cell treatment was well tolerated at all doses. There was no occurrence of neurological worsening or treatment‐related complications. The maximum tested dose of 7.2 × 10^7^ cells was well tolerated with no more safety issues than the two lower cell doses.

![Clinical outcomes through 24‐month visit. Score changes from the baseline are shown. **(A):** An illustration of the three cannula trajectories used for cell administration. **(B):** Fugl‐Meyer Motor Score (mean ± SE). The functional motor score (total 100) at indicated visits postsurgery was subtracted from the baseline score obtained just prior to the stem cell treatment. \*, *p* \< .05; \*\*, *p* \< .01. **(C):** Modified Rankin Scale total score (mean ± SE). The score at indicated visits postsurgery was subtracted from the baseline score obtained just prior to the stem cell treatment. \*, *p* \< .05. **(D):** National Institutes of Health Stroke Scale (mean ± SE). The score at indicated visits postsurgery was subtracted from the baseline score obtained just prior to the stem cell treatment. \*, *p* \< .05. In (B)--(D), mean scores for cohorts (A--C) are also shown as indicated by the legend.](SCT3-8-999-g001){#sct312527-fig-0001}

Imaging Studies {#sct312527-sec-0013}
---------------

The imaging studies of nine subjects used in this study corroborate the clinical outcomes observed. Evidence of mature hemorrhage and encephalomalacia with formation of cerebrospinal fluid‐filled cavity along the presumed implantation needle tract, but separate from the infarct cavity, was observed on postprocedural MRI in one subject. Otherwise, there were no sequelae of acute postprocedural complications observed.

New tissue was observed in all nine subjects by the 6‐month follow‐up, emanating from encephalomalacia infarct cavities. This intracavitary tissue appearance was characterized by the following criteria: short‐term viability (tissue appearance at first postprocedural MRI versus baseline)---nine out of nine cases; growth (new tissue increase across at least two postprocedural MRIs)---six out of six cases available; stabilization (new tissue unchanged across at least two postprocedural MRIs; that is, a growth plateau, up to 24 months)---five out of six cases available; long‐term viability beyond 24 months not available. An example of longitudinal MRI of intracavitary tissue growth is shown in Figure [2](#sct312527-fig-0002){ref-type="fig"}. Such extraneous tissue presence within infarct cavity was obvious in all nine subjects (Fig. [3](#sct312527-fig-0003){ref-type="fig"}).

![An example of longitudinal MRI of intracavitary tissue growth. A subject from group B (\#106) visualized on T1 MRI over time is shown. **(A):** At baseline, **(B)** at 6‐month visit, **(C)** at 12‐month visit, **(D)** at 24‐month visit. The infarct cavity is indicated by an arrow. Two tissue clumps, not present at baseline, presumed to derive from implanted NSI‐566, are seen appearing to fill the cavity slowly over time.](SCT3-8-999-g002){#sct312527-fig-0002}

![MRI of infarct site at the latest follow‐up visit post‐NSI‐566 transplantation. Shown are all nine subjects (\#101--109) visualized on T1 MRI at their latest follow‐up post‐NSI‐566 transplantation. The infarct cavity location is indicated by an arrow. **(A):** \#101, at 24 months, **(B)** \#102, at 12 months, **(C)** \#103, at 14 months, **(D)** \#104, at 9 months, **(E)** \#105, at 14 months, **(F)** \#106, at 24 months, **(G)** \#107, at 21 months, **(H)** \#108, at 12 months, and **(I)** \#109, at 14 months. Growth of new tissue in the infarct cavity is evident in all nine cases.](SCT3-8-999-g003){#sct312527-fig-0003}

Quantitative analyses of imaging data were performed as follows: (a) evaluation of lesion (site of implantation) versus surround tissue characteristics through time: the objective was to test the hypothesis that postimplantation tissue changes in the area of implantation reduce the difference between lesion center and unimplanted surround tissue characteristics, (b) evaluation of crossed cerebellar diaschisis (CCD) through time: the objective was to test the hypothesis that tissue changes at the site of implantation may reverse the secondary impact of stroke on brain tissue remote from the site (diaschisis), in this case the cerebellum, and (c) evaluation of tractography at follow‐up: the objective was to identify traceable white matter tracts outside of the lesion cavity that changed over time in individual subjects. Imaging measurements were performed in Prism View (Prism Clinical Imaging, Inc., Elm Grove, WI, USA RRID:SCR_016977).

### *Evaluation of Lesion Versus Surround* {#sct312527-sec-0014}

To assess the hypothesis that tissue changes were evident after implantation, the lesion versus surround measures at time zero (prior to implantation) were compared with follow‐up imaging results for changes in voxel intensity (see Supporting Information for the method). Comparison of lesion‐free tissue samples would theoretically produce the ratio of 1. The group mean ratios are shown in Table [4](#sct312527-tbl-0004){ref-type="table"}. There were significant changes (*p* \< .05) in the difference between the lesion center and its surrounding tissue at one or more follow‐up times in T1, fractional anisotropy (FA), mean diffusivity (MD), and cerebral blood flow (CBF) signals with *n* = 9 and positron emission tomography (PET) signal with *n* = 8 (one subject \[\#105\] did not receive a follow‐up PET scan). The results suggest significant tissue change in the lesion area versus the surrounding area.

###### 

Ratio of signal between the stroke lesion center and its surrounding tissue

  Visit time (month)   T1 signal   FA signal   MD signal   CBF signal   FDG‐PET signal                                                                                                 
  -------------------- ----------- ----------- ----------- ------------ ---------------- ------- --- ------ ------- ------- --- ------ ------- ------- --- ------ ------- ------- ---- ------
  0                    0.586       0.140       9                        0.438            0.121   9          1.811   0.246   9          0.835   0.105   9          0.737   0.118   9    
  6--10                0.729       0.129       9           .007         0.582            0.141   9   .008   1.520   0.316   9   .016   0.894   0.072   7   .130   Nd      Nd      Nd   Nd
  10--20               0.712       0.134       9           .016         0.571            0.140   8   .014   1.523   0.181   8   .005   0.911   0.088   7   .039   0.848   0.071   8    .006
  \>20                 0.769       0.151       6           .003         0.600            0.193   6   .021   1.509   0.364   6   .014   0.879   0.086   5   .044   0.844   0.044   4    .042

By *t* test (single tail) between baseline (time 0) and a subsequent visit.

Abbreviation: Nd, not done.

### *CCD* {#sct312527-sec-0015}

Seven of the nine subjects exhibited obvious CCD upon visual examination of PET studies at time of implantation, with cerebellar hypometabolism contralateral to the hemisphere containing the stroke lesion. Two subjects (\#108, \#109) showed negligible differences upon visual examination. Contralateral PET samples were significantly lower than ipsilateral samples both at baseline (*p* = .0029, *n* = 9) and follow‐up (*p* = .0214, *n* = 8), confirming that fluorodeoxyglucose (FDG)‐(PET does reflect the CCD effect. Perfusion and diffusion parameters, however, were not significantly different. To assess the hypothesis that cerebellar tissue changes suggestive of a resolution of CCD were evident after implantation, the asymmetry at time zero (implantation) was compared with the asymmetry of the last follow‐up imaging results (12 or 24 months). Single‐tail paired *t* test revealed no significant change in the difference between the ipsilateral and contralateral (CCD‐affected) cerebellum by FA, MD, CBF (*n* = 9), or by PET (*n* = 8; data not shown).

### *Tractography* {#sct312527-sec-0016}

Global tractography was created for each baseline and last follow‐up (12 or 24 months) diffusion tensor imaging (DTI) (*b* = 1,000) scan. Fiber Assignment by Continuous Tracking streamline tracking was performed. In all nine subjects, global tracking (i.e., for the entire brain volume) was visually examined for the presence of major tracts such as the corticospinal tract, which appeared consistent with brain atlas at both baseline and follow‐up. Lesion tracking within the cavity was further evaluated by using the lesion voxels as seeds for tractography. Whether the new tracts in the cavity could be traced to identifiable endogenous tracts and how much of the new tracts might appear to be from the graft were assessed. In four subjects, no tracking resulted within the cavity either at baseline or at follow‐up. In the remaining five subjects (\#101, 104, 106, 108, 109), tracking resulted at the periphery of the lesion in both baseline and follow‐up. There was no consistent difference in the number of tracks or tracking course between baseline and follow‐up. In some subjects, there were substantially overlapping tracks between baseline and follow‐up (\#106, 108, 109), which likely represent white matter tracts present prior to intervention and are not from the de novo growth within the lesion seen in other types of images (Supporting Information Fig. [S2](#sct312527-supitem-0001){ref-type="supplementary-material"}).

### *Motor Task Functional MRI* {#sct312527-sec-0017}

Consistent performance of the motor task was overall lacking. Compliance was also adversely affected by the subjects\' apparent difficulty in segregating left versus right motor function, complicating detection of actual cortical reorganization. Thus, functional MRI (fMRI) was not analyzed.

In all subjects, intracavitary tissue showed no evidence of hypermetabolism, relative to cortex. In some cases, intracavitary tissue was too small to assess the degree of metabolism, whereas in others, low metabolic activity similar to white matter was observed. Tissue MD increased in the postinfarct cavities in all subjects but did not match typical healthy white matter or gray matter. Likewise, T1‐signal and fluid attenuated inversion recovery (FLAIR)‐signal, and T2‐signal did not match healthy gray or white matter. There was no evidence of intracavitary or perilesional increase in ASL signal relative to gray matter that might indicate hyperperfusion, neovascularity, and/or hypermetabolism, which was either unobservable or close to white matter in signal intensity. An example of radiological changes is shown in Supporting Information Figure [S3](#sct312527-supitem-0001){ref-type="supplementary-material"}.

Discussion {#sct312527-sec-0018}
==========

Safety and Maximum Tolerated Dose {#sct312527-sec-0019}
---------------------------------

NSI‐566 is an epigenetically expanded line of primary human neural stem cells (hNSCs) isolated from a single fetal spinal cord tissue. To the best of our knowledge, this is the first study to assess the feasibility and safety of transplanting primary hNSCs into stroke brain in chronic stage. One objective was to determine the maximum tolerated dose (MTD) into the peri‐infarct sites in chronic stroke patients. MTD was assumed by three different factors: (a) the maximum cell density that could be prepared for reproducible injection of viable cells, (b) the maximum volume of cell suspension at the maximum cell density to be safely delivered without causing undue compression on the surrounding tissue, and (c) the maximum feasible number of brain penetrations for depositing the cell suspension at strategic locations. Delivery of 72 million cells distributed across 45 deposits via three penetration tracks was safe. Based on the imaging data of new tissue generation in infarct cavity, further dose escalation based on stroke volume may be another variable to test in future studies in optimizing a maximum therapeutic dose for an individual patient.

Two reports of acute cholecystitis by one patient were the only serious AEs recorded for the study. Although rated as unrelated by the investigator, cyclosporine and tacrolimus are known to be associated with an increased incidence of biliary diseases [24](#sct312527-bib-0024){ref-type="ref"}.

Extent of Therapeutic Effects {#sct312527-sec-0020}
-----------------------------

FMMS improvement of 10 points is considered clinically meaningful [25](#sct312527-bib-0025){ref-type="ref"}, [26](#sct312527-bib-0026){ref-type="ref"}. From the average of all participants across the doses (*n* = 9), the change from baseline in FMMS was 16 points at 12 months, which remained stable to 24 months. This result is further corroborated by the improvement measured by the MRS as well as by the NIHSS. This result is encouraging to move forward to a randomized, sham surgery‐controlled, double‐blind study with a larger cohort size.

It is unknown how long after the injury the brain can retain plasticity and the capability to reorganize neuromuscular communication. It is commonly assumed that this capability decreases with time after injury. Therefore, in this study, we had arbitrarily limited the chronic injury period to no more than 24 months poststroke. Eight participants had their stroke event 12--24 months prior to the stem cell transplantation, while one was at 5 months prior to transplantation. The observations here indicate that the study population is responsive to the hNSC treatment and appropriate for future hNSC trials. We plan to test the time of hNSC treatment poststroke, age, and gender as covariates in future studies.

Potential Mechanism of Therapeutic Action {#sct312527-sec-0021}
-----------------------------------------

Several clinical studies have been reported which evaluated transplantation of other types of cells into basal ganglia of chronic motor stroke patients with similar characteristics to our study [27](#sct312527-bib-0027){ref-type="ref"}, [28](#sct312527-bib-0028){ref-type="ref"}, [29](#sct312527-bib-0029){ref-type="ref"}, [30](#sct312527-bib-0030){ref-type="ref"}, [31](#sct312527-bib-0031){ref-type="ref"}. One was bone‐marrow derived cells genetically modified to transiently overexpress Notch‐1 protein [27](#sct312527-bib-0027){ref-type="ref"}. The other was an immortalized line from a fetal neural tissue [28](#sct312527-bib-0028){ref-type="ref"}, [32](#sct312527-bib-0032){ref-type="ref"}. The presumed mechanism of therapeutic action by these cells is unclear but thought to involve suppression of inflammation.

Throughout various animal studies, one outstanding property of NSI‐566 has been its robust neurogenic potential in vivo, reflected by their ability to send out/receive long‐distance projections and integrate with the host tissue [10](#sct312527-bib-0010){ref-type="ref"}, [11](#sct312527-bib-0011){ref-type="ref"}, [33](#sct312527-bib-0033){ref-type="ref"}. Thus, NSI‐566 has shown the ability to provide neurotrophic support via paracrine factors, achieve synaptic integration with host neurons, and promote regeneration of host neuronal fibers [5](#sct312527-bib-0005){ref-type="ref"}, [10](#sct312527-bib-0010){ref-type="ref"}, [11](#sct312527-bib-0011){ref-type="ref"}. From ALS clinical studies, NSI‐566 transplants survive for long periods with only transient immunosuppression in HLA‐unmatched recepients [17](#sct312527-bib-0017){ref-type="ref"}. Thus, these neurotrophic/neuroregenerative actions by NSI‐566 are expected to be long lasting.

In this study, the facts that, long after cessation of immunosuppressant (first 4 weeks), new tissues appeared and continued to survive in the stroke lesion where NSI‐566 had been injected and that the clinical effects persisted throughout 24 months suggest that the mode of action by NSI‐566 is regeneration rather than anti‐inflammation, although immunomodulatory effects cannot be ruled out and could explain some of the changes seen in imaging. Long‐term survival of NSI‐566 in ALS patients with only transient immunosuppression has been observed by autopsy [17](#sct312527-bib-0017){ref-type="ref"} as well as by clinical effects [18](#sct312527-bib-0018){ref-type="ref"}. A recent study in SCI primates has also demonstrated a regenerative pathway in which synaptic integration of NSI‐566 neurons with host circuitry resulted in motor recovery [11](#sct312527-bib-0011){ref-type="ref"}.

New tissue observed on MRI was present within subcortical stroke cavities at the initial 6‐month postprocedural MRI for all nine subjects. Cells were injected into white matter surrounding postinfarct cavities, and not directly into the cavities. The new tissues appear to originate from injection sites in the border of cavity. The absence of supranormal metabolic activity on FDG‐PET/CT or supranormal signal at ASL perfusion within intracavitry and pericavitary tissues, supports the idea that the new tissue growth is not aggressive. Still, the data cannot prove 100% tissue stability or its origin at this time.

In a phase I study of CTX0E03, a neural tissue‐derived immortalized clonal cell line transplanted into a similar subcortical location in chronic stroke patients, researchers described hyperintensity around the needle injection tract on MRI T2‐FLAIR images [28](#sct312527-bib-0028){ref-type="ref"}. In our study, T1 as well as T2 FLAIR imaging at follow‐up versus baseline did not identify hyperintensity along the needle tracts. The changes were in the infarct and peri‐infarct areas.

In animal studies of SCI, traumatic brain injury, and ischemic stroke, implantation of NSI‐566 during acute or subacute period has consistently produced cavity‐filling tissue by the cells [8](#sct312527-bib-0008){ref-type="ref"}, [9](#sct312527-bib-0009){ref-type="ref"}, [10](#sct312527-bib-0010){ref-type="ref"}, [11](#sct312527-bib-0011){ref-type="ref"}, [13](#sct312527-bib-0013){ref-type="ref"}, [34](#sct312527-bib-0034){ref-type="ref"}. Still, it is surprising that such cavity‐filling effect is observed in a human brain tissue lesioned 2 years prior to the cell implantation. This suggests that the human brain may remain malleable for regeneration for 2 years or more.

The macromolecular environment and microstructure of the implanted stem cell tissue is unknown, but differs from either gray matter or white matter. New intracavitary tissue did not exactly follow gray matter or white matter tissue profiles at standard MRI (T1‐signal, FLAIR‐signal, and T2‐signal) or DTI (MD). This may indicate atypical cell structure, atypical myelination, and/or reactive glial response, which are expected of an ectopic hNSC‐derived tissue. Quantitative analyses of the lesion (cavity) and surrounding tissue over time in T1, FA, MD, CBF, and FDG‐PET parameters indicate significant changes in the lesion toward the surrounding tissue by all parameters at 12 and 24 months. Motor task fMRI was too variable to be analyzed, reflecting the difficulty of acquiring task fMRI in varying degrees of hemiparetic stroke patients. We will explore incorporation of task‐free resting‐state fMRI in future studies.

PET/CT imaging revealed that intracavitary and pericavitary tissue were hypometabolic relative to gray matter, and closer to white matter when it was observable. Remote pathology due to stroke, CCD, showed significant hypometabolism in cerebellum contralateral to the stroke hemisphere in FDG‐PET in some participants. Although intra/pericavity PET signal improved toward the surround nonlesional signal, there were no significant changes in the cerebellar PET signal over time. Thus, anatomical changes appear to be confined within the proximity of the stem cell implantation. Adjuntive physical rehabilitation may improve this situation.

Tractography was also conducted over the 24 months. In five participants, new tracts were identifiable but could not be traced into or out of the cavity. This is not altogether surprising, as tracking is limited in spatial resolution (order of millimeters) and assumes organized, tract‐like structure of white matter. The absence of tracking suggests that any new, functional neural connections do not possess the multicellular organization of intact white matter tracts. The trend of white matter‐related parameters, such as fractional anisotropy to change in the direction of functioning white matter, still supports the possibility that new neural tissue has formed. One possible mode of action may be that any stem cell‐derived tissue is largely composed of interneurons and glia, which promote regeneration of the existing circuitry and serve as bridges between such regenerating neuronal fibers. Such effect of NSI‐566 had been observed in a rat model of ischemic SCI [12](#sct312527-bib-0012){ref-type="ref"} as well as in a nonhuman primate model of traumatic SCI [11](#sct312527-bib-0011){ref-type="ref"}.

Conclusion {#sct312527-sec-0022}
==========

Transplantation of human spinal cord‐derived neural stem cells into the peri‐infarct area in stable stroke patients was well tolerated and suggested preliminary clinical benefits as measured by three different clinical outcome measures. Results from imaging studies indicate new neural tissue formation in the stem cell implantation area. These results warrant a larger, randomized, controlled, double‐blind study.
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